Kinnate Biopharma Inc.
KNTE · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $110,384 | $268,801 | $772,613 | $1,729,533 |
| - Cash | $56,998 | $29,261 | $116,096 | $365,462 |
| + Debt | $3,175 | $4,182 | $0 | $0 |
| Enterprise Value | $56,561 | $243,722 | $656,517 | $1,364,071 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$799 | -$604 | -$123 | -$83 |
| % Margin | – | – | – | – |
| EBITDA | -$118,209 | -$117,917 | -$89,988 | -$35,918 |
| % Margin | – | – | – | – |
| Net Income | -$112,649 | -$114,021 | -$89,415 | -$35,433 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.42 | -2.59 | -2.05 | -0.81 |
| % Growth | 6.6% | -26.3% | -153.1% | – |
| Operating Cash Flow | -$100,043 | -$89,034 | -$71,065 | -$30,181 |
| Capital Expenditures | $0 | -$2,719 | -$769 | -$297 |
| Free Cash Flow | -$100,043 | -$91,753 | -$71,834 | -$30,478 |